P&G Q1 FY2026: Sales +3%, EPS +21%, Outlook Reaffirmed

Procter & Gamble reported a 3% increase in sales in Q1 of fiscal 2026 and a 21% rise in diluted earnings per share. The company said it continues to expect its previously issued FY2026 outlook and reiterated that guidance at the quarter update. For investors, the combination of modest top-line growth with a materially larger EPS uplift points to margin improvement or favorable mix and execution versus the year-ago quarter. Context from FY2025 results highlights the scale behind these moves: P&G posted FY2025 net sales of $84.3 billion (flat versus FY2024), net earnings of $16.0 billion (up 7%) and diluted EPS of $6.51 (up 8%). Q1 performance should be read against that base—management is pursuing a “balanced top/bottom-line” approach under a longer-term algorithm targeting 2–4% organic sales growth and roughly 10% core EPS growth.

P&G sells across five reportable segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. In FY2025 the largest category exposure by share of net sales included Fabric Care at 23% and Home Care at 13%; Baby, Feminine & Family Care and Health Care each contributed roughly 9–6% bands across categories. On a segment basis for FY2025, Fabric & Home Care generated $29.6 billion in net sales, Baby/Feminine/Family Care $20.2 billion, Health Care $12.0 billion and Grooming $6.7 billion. Geographically, more than half of P&G’s annual net sales originate outside the U.S.; U.S. net sales were $13.9 billion (16.5% of total) versus $70.4 billion international (83.5%). That mix makes reported results and guidance sensitive to currency moves and regional demand differences—factors the company identified as material in prior filings.

P&G’s filings characterize its strengths as brand leadership, scale and execution rather than a structural economic moat. The company cites market-share leadership in core categories (for example, global fabric care leadership via Tide/Ariel) as an execution advantage. Brands are carried as indefinite-lived intangibles (Gillette carrying value cited at $12.8 billion after a $1.3 billion impairment), and management’s innovation focus centers on product superiority, packaging and consumer insights rather than patent exclusivity. Fiscal 2025 intangible balances included $2.8 billion gross in patents/technology and larger indefinite-lived brand carrying values. The outsize EPS increase relative to sales growth in Q1 suggests operating leverage, pricing execution or mix benefits were in play. Given P&G’s exposure to commodities and FX, continued margin momentum will depend on raw-material cost trends, pricing actions and international currency movement.

P&G’s principal risk themes remain legal and regulatory exposures, macro/FX sensitivity, commodity cost volatility and portfolio/operational execution. Specific items called out in filings include an uncertain tax liability of $634 million (up from $582 million), FY2025 restructuring charges of about $1.1 billion (74% cash-settled with $189 million accruals remaining) and single-source supplier risks for some inputs. The company also notes that weakening currencies can reduce reported sales (FY2025 currency effects reduced sales by ~1%). Investors should weigh these risks against P&G’s capital allocation and productivity targets: management has an objective of 90%+ adjusted free-cash-flow productivity (FY2025 recorded 87%) and a long-term algorithm for modest organic growth paired with outsized core EPS gains.